NASDAQ:AKAN - CA00971M4039 - Common Stock
AKAN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AKAN have multiple concerns. AKAN has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -51.76% | ||
ROE | -95.78% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 24.91% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.08 | ||
Debt/FCF | N/A | ||
Altman-Z | -11.24 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.39 | ||
Quick Ratio | 1.39 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
3.45
-0.09 (-2.54%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.01 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.59 | ||
P/tB | 0.59 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -51.76% | ||
ROE | -95.78% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 24.91% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.08 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 1486.96% | ||
Cap/Sales | 250.76% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.39 | ||
Quick Ratio | 1.39 | ||
Altman-Z | -11.24 |